DavidBadeschMD

Pulmonology • Aurora, CO

Critical Care Medicine, Pulmonary Vascular Medicine

Professor of Medicine, University Colorado

Join to view full profile

Dr. Badesch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Badesch's full profile

Already have an account?

Office
12605 E 16th Ave
# F402
Aurora, CO 80045
Phone+1 720-848-5300

Fax+1 720-848-0480

Education & Training

University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1987 - 1989
University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1987
Vanderbilt University Medical CenterResidency, Internal Medicine, 1983 - 1986
University of Virginia School of MedicineClass of 1983

Certifications & Licensure

CO State Medical License 1987 - 2025
TN State Medical License 1985 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension Start of enrollment: 2006 Feb 01
Terminated
Phase 3
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2006 May 01
Completed
Phase 4
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management Start of enrollment: 2006 Mar 01
Completed
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
Completed
Phase 2
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program Start of enrollment: 2011 Jun 01
Completed
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
Completed
Phase 3
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Start of enrollment: 2013 Sep 11
Completed
Phase 3
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Beraprost-314d Added-on to Tyvaso® (BEAT) Start of enrollment: 2013 May 31
Completed
Phase 3
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Start of enrollment: 2014 May 31
Completed
Phase 2
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Pulmonary Hypertension Association Registry Start of enrollment: 2015 Oct 01
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies.
Marius M Hoeper, Stephan Rosenkranz, David B Badesch, Marc Humbert, David Langleben
Respiratory Medicine. 2024-12-10
Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.
Mardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, Ekkehard Grünig, Marius M Hoeper
The Journal of Heart and Lung Transplantation. 2024-12-05
Case report: A finding of PVOD and PAH in first degree relatives suggests shared heritable risk and overlapping features of both pulmonary vascular diseases.
Roger Winters, Lindsay M Forbes, Dunbar Ivy, Carlyne Cool, Bryan D Park
Respirology Case Reports. 2024-11-01

Lectures

Advances in Pulmonary & Critical Care Medicine
Inova Health System, Falls Church, Virginia - 3/16/2013

Press Mentions

A Grateful Couple Supports CU Pulmonary Hypertension Research with Endowed ChairAugust 2nd, 2024
Time from PAH Diagnosis Impacts Prognosis, Response to SelexipagAugust 5th, 2021
Clinical Challenges: Genetic Insights into Pulmonary Arterial HypertensionNovember 2nd, 2020
Join now to see all